GLP-1 Market
LLY $1138.28 ▲ +2.0% NVO $43.45 ▲ +0.9% PFE $27.72 • 0.0% VKTX $31.53 ▼ -1.4% KLRA $13.75 ▼ -1.4% GPCR $38.44 ▼ -0.6% RHHBY $54.80 ▲ +3.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Allisartan Isoproxil

Company
XueQing Yu
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for Allisartan Isoproxil and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03264352

    Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

    Not yet reported XueQing Yu 11414 participants Est. completion 2029-09-01 1 site
    Type 2 diabetes Other conditions: Adverse Event, Blood Pressure, Prehypertension, Cardiovascular Risk Factor
    View official trial listing →
  • Recruiting NCT NCT07174830

    Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

    Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 54 participants Est. completion 2026-02-16 1 site
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT02893358

    Antihypertensive Treatment in Masked Hypertension

    Not yet reported Yan Li 320 participants Est. completion 2022-03-30 1 site
    Other conditions: Masked Hypertension
    View official trial listing →
  • Active, not recruiting NCT NCT04111419

    Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation

    Not yet reported Shanghai Jiao Tong University School of Medicine 1200 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Atrial Fibrillation, Hypertension
    View official trial listing →
  • Withdrawn NCT NCT04978649

    Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy

    Not yet reported Guangdong Provincial People's Hospital Est. completion 2028-07-31
    Type 2 diabetes Other conditions: Blood Pressure
    View official trial listing →
  • Completed NCT NCT06465264

    To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

    Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 499 participants Est. completion 2023-02-24 1 site Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT06500689

    To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

    Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 366 participants Est. completion 2024-05-24 40 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Allisartan Isoproxil, Xinlitan

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.